Efficacy and Safety Study of Bimatoprost Sustained-Release (SR) in Participants With Open-angle Glaucoma or Ocular Hypertension

Recruiting

I'm Interested

Trial ID: NCT02247804

Age - 18 Years-N/A Condition - Glaucoma Gender - All Accepting Healthy Volunteers - No

Purpose

This study will evaluate the efficacy and safety of bimatoprost SR in participants with open-angle glaucoma or ocular hypertension. The study includes a 12-month treatment period with an 8-month extended follow-up.

Official Title

The Efficacy and Safety of Bimatoprost SR in Patients With Open-angle Glaucoma or Ocular Hypertension

Stanford Investigator(s)

Ann Caroline Fisher, MD
Ann Caroline Fisher, MD

Clinical Associate Professor, Ophthalmology

Eligibility


Inclusion Criteria:

-Diagnosis of either open-angle glaucoma or ocular hypertension in each eye and both eyes
require IOP-lowering treatment.

Exclusion Criteria:

   - Previous enrollment in another Allergan Bimatoprost SR Study.

   - Eye surgery (including cataract surgery) and/or any eye laser surgery within the past
   6 months in the study eye

   - Anticipated need for laser eye surgery in either eye within the first 52 weeks of the
   study duration

   - History of glaucoma surgery

View More
View Less

Intervention(s):

drug: Timolol Vehicle (placebo)

drug: Bimatoprost SR

drug: Active Comparator: Timolol 0.5%

other: Sham: Applicator Without Needle

Recruiting

I'm Interested

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Kristina Liu
(408) 726-5119

©2024 Stanford Medicine